Dr David Ross     Dr Deborah White

 Session 3: Future directions for CML

• TFR trial update 
  (Dr David Ross)
• Biomarkers and response prediction 
  in CML
  (Dr Deborah White)

TFR trial update
Dr David Ross- SA Pathology, Universities of Adelaide and South Australia

• Deep molecular response and treatment-free remission
• Imatinib TFR findings
• TFR experience with nilotinib and dasatinib
• Maximising eligibility for TFR
• Future and ongoing research questions
• Conclusions and practical recommendations

Biomarkers and response prediction in CML
Dr Deborah White - SAHRMI, University of Adelaide

• Chemokines, cytokines and growth factors
• KIR genotypes
• CIP2A
• Drug transporters
• Genomics
• Drug monitoring and compliance